Stockwinners Market Radar for March 16, 2022 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

19:51 EDT Activision Blizzard COO sells $1.16M in common stock - In a regulatory filing, Activision Blizzard disclosed that its COO Daniel Alegre sold 14.5K shares of common stock on March 14th in a total transaction size of $1.16M.

19:41 EDT Bristol-Myers EVP sells $2.04M in common stock - In a regulatory filing, Bristol-Myers disclosed that its EVP and Chief Commercial Officer Christopher Boerner sold 29.5K shares of common stock on March 14th in a total transaction size of $2.04M.

19:22 EDT Ionis Pharmaceuticals announces publication of positive donidalorsen ph. 2 data - Ionis Pharmaceuticals "announced the publication of positive Phase 2 data for donidalorsen in the New England Journal of Medicine available at NEJM.org. Donidalorsen is an investigational antisense medicine Ionis is evaluating for treating patients with hereditary angioedema, HAE. In the Phase 2 study, donidalorsen demonstrated a 90% reduction in angioedema attacks compared with placebo at the 80 mg monthly dose. There was significant improvement in quality of life as assessed by the Angioedema Quality of Life Questionnaire in the patients treated with donidalorsen. Patients reported higher overall health-related quality of life over 17 weeks with donidalorsen, with a mean change in total score of the AE-QoL of -26.85, compared with -6.15 in the placebo group where reduction in the score indicates better quality of life. There were improvements observed across all individual domains of the AE-QoL compared with placebo. The majority of adverse events during the study were mild with a frequency that was similar between patients receiving donidalorsen and placebo groups. There were no deaths or serious adverse events. The most common treatment-emergent adverse events (TEAEs) reported in patients treated with donidalorsen were headache and nausea, both of which occurred at a higher incidence in the placebo group. None of the patients discontinued treatment due to adverse events."

19:13 EDT Northern Trust raise prime rate to 3.5% from 3.25% - The Northern Trust Company has increased its prime rate from 3.25% to 3.50%, effective Thursday, March 17, 2022.

18:20 EDT HSBC Bank USA, affiliates raise prime and reference rate to 3.5% from 3.25% - HSBC Bank USA, N.A., and its affiliates announced that they have raised their prime and reference rate to 3.50% from 3.25%, effective tomorrow.

18:03 EDT ZTO Express declares special dividend of 25c per share - The board of directors has approved a special dividend of 25c per ADS and share for 2021 to shareholders of record as of the close of business on April 8. The payment date is expected to be April 22 for holders of class A ordinary shares and on April 27 for holders of ADSs.

17:58 EDT PNC Bank raises prime lending rate to 3.5% from 3.25% - PNC Bank, N.A. announced an increase in its prime lending rate. The new rate of 3.50% is effective tomorrow, March 17, 2022.

17:50 EDT Senator Elizabeth Warren introduces legislation to limit 'Big Tech' mergers - United States Senator Elizabeth Warren, D-Mass. and United States Representative Mondaire Jones, D-N.Y. introduced bicameral legislation United States Senator Elizabeth Warren and United States Representative Mondaire Jone "introduced bicameral legislation to help stomp out rampant industry consolidation that allows companies to raise consumer prices and mistreat workers. The Prohibiting Anticompetitive Mergers Act would ban the biggest, most anticompetitive mergers and give the Department of Justice, DOJ. and Federal Trade Commission, FTC, the teeth to reject deals in the first instance without court orders and to break up harmful mergers...Without robust competition, large opportunistic corporations are able to use inflation as a pretext to abuse their pricing power and jack up prices for American consumers at the grocery store, at the gas pump, and at the pharmacy. This excessive market power costs American families $5,000 per year on average and has depressed median household wages by $10,000.," said the statement by the U.S. Senators. "For the last five decades, big companies have had almost free reign over our economy, squashing competitors, growing bigger and bigger, and abusing their market power to price gouge consumers and crush workers and small businesses. This unconstitutional behavior has to stop. My new bill with Rep. Jones would restore our country's anti-monopoly tradition by banning the biggest, most anticompetitive mergers and giving the DOJ and the FTC stronger tools to enforce our antitrust laws and restore real competition in our markets. Congress needs to take bold action to bring down prices for families and promote a fairer economy for all Americans, and our bill would do just that," said Senator Warren. Companies targed for anticompetitive behavior in the past by Sen Warren include Apple(AAPL), Amazon (AMZN) and Google (GOOG). Reference Link

17:39 EDT SoFi Technologies CEO buys $150K in common stock - In a regulatory filing, SoFi Technologies disclosed that its CEO Anthony Noto bought 17.4K shares of common stock on March 16th in a total transaction size of $149.8K.

17:35 EDT AbbVie's Rinvoq approved by FDA for ulcerative colitis - AbbVie announced that the FDA has approved Rinvoq for the treatment of adults with moderately to severely active ulcerative colitis who have had an inadequate response or intolerance to one or more tumor necrosis factor blockers. This FDA approval is the first indication for Rinvoq in gastroenterology and is supported by efficacy and safety data from three Phase 3 clinical studies. Across all clinical trials, significantly more patients treated with Rinvoq achieved clinical remission at weeks 8 and 52, the primary endpoint. In addition, the studies met all ranked secondary endpoints. At week 8, 26% and 33% of patients treated with Rinvoq 45 mg achieved clinical remission, the primary endpoint based on mMS, compared to 5 percent and 4 percent of patients who received placebo. Onset of response occurred as early as Week 2, with a greater proportion of patients receiving Rinvoq 45 mg once daily achieving clinical response. During the maintenance trial, 42% and 52% of patients treated with Rinvoq 15 mg or 30 mg, respectively, achieved clinical remission at week 52, the primary endpoint, compared to 12% of patients who received placebo. Overall, the safety profile observed in patients with UC treated with Rinvoq was generally similar to the safety profile in patients with RA and AD.

17:31 EDT U.S. Bancorp raises prime lending rate to 3.5% - U.S. Bancorp announced it has increased its prime lending rate to 3.5% from 3.25%, effective tomorrow, March 17, at all U.S. Bank locations.

17:24 EDT Instagram debuts Family Center, tools for parent to manage teen's experiences - Instagram chief Adam Mosseri, blogged in part, earlier: "Today, we're introducing Family Center, a new place for parents and guardians to access supervision tools and resources from leading experts. Supervision tools are available on Instagram today, and will begin rolling out in VR in May. This is the first step in a longer term journey to develop intuitive supervision tools, informed by experts, teens and parents. Our vision for Family Center is to eventually allow parents and guardians to help their teens manage experiences across Meta technologies, all from one central place. Parents and guardians know what's best for their teens, and in December I committed to developing new supervision tools that allow them to be more involved in their teens' experiences. Today, we're making these supervision tools available in our new Family Center. We worked closely with experts, parents, guardians and teens to develop Family Center, a new place for parents to oversee their teens' accounts within Meta technologies, set up and use supervision tools, and access resources on how to communicate with their teens about internet use. This is just one step on a longer path - our vision for Family Center is to eventually allow parents and guardians to help their teens manage experiences across Meta technologies, all from one central place." Reference Link

17:18 EDT Retail Value closes sale of Crossroads Center, delisting from NYSE - Retail Value announced that the general due diligence period expired under an agreement to sell Crossroads Center located in Gulfport, Mississippi to a third-party purchaser for $38.5M in cash, subject to adjustment for certain closing pro-rations, allocations, credits and closing costs. Closing remains subject to customary conditions, including the receipt of tenant estoppels and the consent of the ground lessor to the assignment of the ground lease applicable to the shopping center, and is expected to occur by the end of April. In addition, in connection with the effectiveness of the Crossroads Centers purchaser's obligations, the company intends to provide notice to the NYSE of its intention to voluntarily de-list its common shares. The company expects that the de-listing of its common shares will occur prior to the commencement of trading on April 7. The company has not arranged for listing and/or registration of its common shares on another national securities exchange or for quotation of its common shares in a quotation medium.

17:15 EDT Citizens Financial raises prime lending rate to 3.50% from 3.25% - Citizens Financial has raised its prime lending rate to 3.50% from 3.25%, effective Thursday, March 17.

17:03 EDT Ashland increasing prices up to 15% - Ashland will increase prices up to 15% or as contracts allow effective April 1, to cover general inflation related to raw materials, energy, freight, and labor. The price increase includes all Ashland products across all the markets and applications the company serves including life sciences, personal care, specialty additives and intermediates.

16:57 EDT Ellington Financial reports book value per share of $17.85 as of February 28 - Ellington Financial announced its estimated book value per share of common stock of $17.85 as of February 28, 2022. This estimate includes the effect of the previously announced monthly dividend of $0.15 per share of common stock, payable on March 25, 2022 to holders of record on February 28, 2022, with an ex-dividend date of February 25, 2022.

16:46 EDT Wells Fargo to raise prime rate to 3.5% - Wells Fargo said it is increasing its prime rate to 3.5% from 3.25%, effective March 17.

16:44 EDT Perma-Pipe awarded contracts totaling over $15.5M in Saudi Arabia, Egypt - Perma-Pipe International Holdings, Inc. announced it has recently been awarded contracts totaling in excess of $15.5M in Saudi Arabia and Egypt. Projects will be executed in Perma-Pipe's facilities during Q1 2022. The newly awarded projects are part of major infrastructure developments in King Salman Park, Security Forces Medical City - Riyadh, King Abdullah International Gardens, Saudi Arabia, and Ain Shams University in the New Capital City, Egypt. The projects will utilize Perma-Pipe's XTRU-THERM insulation system, a spray-applied polyurethane foam jacketed with a high-density polyethylene casing, fabrication and coating capabilities. The PermAlert leak detection system will also be supplied with the insulated pipelines. Raed Al Saleh, General Manager for Perma-Pipe Saudi Arabia states, "We are delighted with these contract awards at the start of 2022, which is shaping up to be another successful year."

16:35 EDT Workhorse Group CEO buys $155K in common stock - In a regulatory filing, Workhorse Group disclosed that its CEO Richard Dauch bought 50K shares of common stock on March 14th in a total transaction size of $155K.

16:34 EDT Eneti announces Seajacks signs new maintenance contract - Eneti announced that Seajacks UK Limited, a wholly-owned subsidiary of the company and a provider of installation and maintenance vessels to the offshore wind sector, has signed a new contract with a global original equipment manufacturer for wind turbine operation and maintenance in NW Europe for one of its NG2500-class vessels. The contract, which has a duration of between 90 and 180 days, will generate approximately $3.85M to $7.45M of revenue in the second and third quarters of 2022.

16:30 EDT Regions Bank raises prime lending rate to 3.5% from 3.25% - Regions Bank announced it is increasing the Regions prime lending rate to 3.50% from 3.25%, effective Thursday, March 17.

16:27 EDT Guess falls 4.5% to $18.48 after Q4 earnings miss

16:21 EDT Citi raises base lending rate to 3.5% from 3.25% - Citibank said it has raised its base lending rate to 3.50% from 3.25%, effective tomorrow, Thursday, March 17, 2022.

16:19 EDT Guess board expands buyback by $100M - On March 14, 2022, the Board of Directors expanded its repurchase authorization by $100M, leaving a new capacity of $249.0 million. In connection with this expanded authorization, the Company intends to enter into an accelerated share repurchase arrangement with a financial institution under which it will repurchase $175.0M of its common stock on terms to be negotiated, subject to customary conditions.

16:16 EDT Seer announces appointment of Scott Thomas as Chief Commercial Officer - Seer announced the appointment of Scott D. Thomas as Chief Commercial Officer effective March 21. Mr. Thomas joins Seer from Singular Genomics, where he served as Senior Vice President, Sales and Marketing. Prior to Singular, he spent over two decades with increasing commercial responsibilities within the life sciences industry, including 11 years at Illumina. "I'm thrilled to welcome Scott, whose leadership and breadth of expertise in the commercialization of life sciences tools complements the balance of our talented executive team," said Omid Farokhzad, Chief Executive Officer and Chair of Seer. "As we accelerate our commercial efforts following the broad release of our Proteograph Product Suite, we're excited to have Scott lead the expansion and building of our global commercial organization, and to leverage his extensive knowledge of markets around the world to reach and empower a broad range of customers to achieve exceptional outcomes."

16:09 EDT Vacasa reports Q4 Nights Sold 1.1M, a 55% year-over-year increase. - Reports Q4: Gross Booking Value per Night Sold was $347, a 27% year-over-year increase. Gross Booking Value was $379 million, a 96% year-over-year increase.

16:06 EDT Box sees revenue growth of 15%-17% in FY25 - As part of its Long-Term Financial Model, Box provided financial targets for its fiscal year ending January 31, 2025: Combined revenue growth plus free cash flow margin is expected to be 43%-44%. Revenue growth is expected to be in the range of 15%-17% year-over-year. Non-GAAP gross margin* is expected to be approximately 77%. Non-GAAP operating margin* is expected to be in the range of 25%-28%.

16:05 EDT Box announces new $150M buyback

15:59 EDT Level One raises quarterly cash dividend to 7c from 6c per share - Level One Bancorp, the holding company for Level One Bank, announced that the board of directors of had declared a quarterly cash dividend on its common stock of 7c per share payable on April 15 to shareholders of record on March 31.

15:35 EDT Netflix looks to limit account sharing, amid drive for 'great' content - Netflix Director, Product Innovation Chengyi Long blogged: "We've always made it easy for people who live together to share their Netflix account, with features like separate profiles and multiple streams in our Standard and Premium plans. While these have been hugely popular, they have also created some confusion about when and how Netflix can be shared. As a result, accounts are being shared between households - impacting our ability to invest in great new TV and films for our members. So for the last year we've been working on ways to enable members who share outside their household to do so easily and securely, while also paying a bit more. And over the next few weeks, we'll launch and test two new features for our members in Chile, Costa Rica, and Peru: Add an Extra Member: Members on our Standard and Premium plans will be able to add sub accounts for up to two people they don't live with - each with their own profile, personalized recommendations, login and password - at a lower price: 2,380 CLP in Chile, 2.99 USD in Costa Rica, and 7.9 PEN in Peru; Transfer Profile to a New Account: Members on our Basic, Standard, and Premium plans can enable people who share their account to transfer profile information either to a new account or an Extra Member sub account - keeping the viewing history, My List, and personalized recommendations. We recognize that people have many entertainment choices, so we want to ensure any new features are flexible and useful for members, whose subscriptions fund all our great TV and films. We'll be working to understand the utility of these two features for members in these three countries before making changes anywhere else in the world." Reference Link

15:13 EDT Truist Financial to increase prime rate to 3.5% - Truist Financial announced an increase in its prime lending rate to 3.5% from 3.25%, effective March 17.

15:08 EDT M&T Bank increases prime lending rate to 3.5% from 3.25% - Effective Thursday, March 17, M&T Bank will increase its prime lending rate from 3.25% to 3.50%, the bank announced.

14:31 EDT MoneyGram agrees to settle legacy enforcement matter with NYDFS - MoneyGram announced it has reached a final agreement to settle its previously disclosed legacy enforcement matter with the New York Department of Financial Services, or "NYDFS," through a consent order. Pursuant to the agreement, MoneyGram will pay a civil monetary penalty of $8.25M to the NYDFS and undertake various reporting obligations. This payment is consistent with the estimated amount that MoneyGram previously accrued in the fourth quarter of 2021, the company stated. "We're pleased that this legacy matter from many years ago is now behind us. MoneyGram continues to work diligently to prevent its systems from being used to perpetrate any unlawful activity. Building an industry-leading compliance program has for years been front and center of our commitment to protecting our customers and communities," said Alex Holmes, MoneyGram's chairman and CEO.

13:33 EDT AstraZeneca, Merck announce 'further positive results' from OlympiA trial - AstraZeneca (AZN) and Merck (MRK) announced what the companies identify as "further positive results" from the OlympiA Phase 3 trial, which showed LYNPARZA demonstrated a statistically significant and clinically meaningful improvement in overall survival versus placebo in the adjuvant treatment of patients with germline BRCA-mutated, or gBRCAm, high-risk human epidermal growth factor receptor 2-negative early breast cancer who had completed local treatment and standard neoadjuvant or adjuvant chemotherapy. Primary results from the OlympiA Phase 3 trial were first presented during the 2021 American Society of Clinical Oncology Annual Meeting and are published in The New England Journal of Medicine. The OS data and the primary results formed the basis for the recent approval by the US Food and Drug Administration of LYNPARZA in this setting, the companies noted. The additional results were presented today at a European Society for Medical Oncology Virtual Plenary. In the key secondary endpoint of OS, LYNPARZA reduced the risk of death by 32% versus placebo. LYNPARZA improved the three-year survival rate to 92.8% versus 89.1% for those on placebo. At four years, the survival benefit was maintained with 89.8% of patients treated with LYNPARZA alive versus 86.4% of those on placebo. The safety and tolerability profile of LYNPARZA in this trial was in line with that observed in prior clinical trials, the companies said.

13:11 EDT Howard Schultz to return to Starbucks as interim CEO - Howard Schultz to return to Starbucks as interim CEO starting April 4th as CEO Kevin Johnson steps down. The company expects new CEO to be appointed this fall. Comments taken from Starbucks 2022 Annual Meeting of Shareholders.

12:24 EDT CP commits to clarifying train traffic data submitted as part of KCS deal review - Canadian Pacific Railway Limited made a statement in response to the Surface Transportation Board's decision on Wednesday asking Applicants to "address an apparent inconsistency in certain data submitted" to the STB. The company said: "CP welcomes and expects a comprehensive regulatory and environmental review of our application and shares the STB's desire for accurate, consistent information across all aspects of that review. As called for by the decision, CP will submit to the STB by March 21 a full explanation of the data submitted with its Application and shared with the Board's Office of Environmental Analysis in connection with its review of the Application. We look forward to the STB restarting the procedural schedule for its review of the proposed CP-KCS transaction following its review of the explanation Applicants will provide."

12:00 EDT Endeavour Silver falls -10.1% - Endeavour Silver is down -10.1%, or -54c to $4.83.

12:00 EDT Direxion Daily Semiconductor Bear 3X Shares falls -12.3% - Direxion Daily Semiconductor Bear 3X Shares is down -12.3%, or -61c to $4.35.

12:00 EDT Dingdong rises 53.0% - Dingdong is up 53.0%, or $1.35 to $3.90.

11:59 EDT Southern States Bancshares appoints Mark Chambers as CEO of Southern States Bank - Southern States Bancshares, the holding company for Southern States Bank, announced the appointment of Mark Chambers to the board of directors of the company and the bank. In addition to continuing to serve as President of both the company and the bank, Chambers was appointed CEO of the bank. Chambers has served as president of both Southern States and the bank since 2019.

11:57 EDT Biogen announces publication of ADUHELM Phase 3 EMERGE, ENGAGE data - Biogen announced that The Journal of Prevention of Alzheimer's Disease published a peer-reviewed manuscript detailing data from the pivotal Phase 3 EMERGE and ENGAGE trials for ADUHELM 100 mg/mL injection for intravenous use in early Alzheimer's disease. The publication includes results from the primary, secondary and tertiary endpoints in the trials, as well as safety data and biomarker sub-studies. In June 2021, the U.S. Food and Drug Administration granted accelerated approval for ADUHELM as the first Alzheimer's disease treatment to address a defining pathology of the disease. ADUHELM is indicated for the treatment of Alzheimer's disease. Treatment with ADUHELM should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in clinical trials. There are no safety or effectiveness data on initiating treatment at earlier or later stages of the disease than were studied. This indication is approved under accelerated approval based on reduction in amyloid beta plaques observed in patients treated with ADUHELM. Continued approval for this indication may be contingent upon verification of clinical benefit in confirmatory trial. "We are pleased that the peer-reviewed manuscript is now available to provide physicians with a greater understanding of the appropriate use of ADUHELM," said Samantha Budd Haeberlein, Ph.D., SVP, Head of Neurodegeneration Development at Biogen. "We will continue to provide physicians with efficacy and safety data to help them make the best treatment decisions for patients as we learn from our ongoing trials and real-world evidence."

11:36 EDT Kohl's jumps 15% to $62 after WSJ report of planned takeover bids

11:20 EDT Brown-Forman appoints Dan Muraski as CIO, Sailaja Kotra-Turner as CISO - Brown-Forman Corporation announces the appointment of Dan Muraski to the role of Chief Information Officer and Sailaja Kotra-Turner to the role of Chief Information Security Officer, effective immediately. Muraski has been at Brown-Forman for more than 12 years in a variety of IT roles. Most recently, he was the vice president, director, global enterprise applications and the portfolio management office. Kotra-Turner has been with Brown-Forman since September 2020 as global director, IT security, and governance.

11:06 EDT Natera director Roelof Botha invests $5M in the company - Natera announced that Roelof Botha, lead independent director of Natera's board of directors and partner at Sequoia Capital, has invested $5M to purchase shares of Natera's stock on the open market. In addition, Natera executives and non-employee directors have elected to exchange their cash compensation for Natera equity for the remainder of 2022.

10:58 EDT Rennova Health completes 1-for-10,000 reverse stock split - Rennova Health announced that effective at 5:00 pm, Eastern Time, on March 15, 2022, the Company completed a 1 for 10,000 reverse stock split of its outstanding common stock. The Company's common stock will open for trading on Wednesday March 16, 2022, on a post-split basis and trade under the symbol RNVAD for 20 days. As a result of the reverse stock split, every 10,000 shares of the Company's common stock issued and outstanding on the Effective Time will be consolidated into one issued and outstanding share, except to the extent that the reverse stock split results in any of the Company's stockholders owning a fractional share, which fractional share will be in that case paid in cash. In connection with the reverse stock split, there will be no change in the nominal par value per share of $0.0001. Based on the number of shares outstanding on March 9, 2022, the reverse stock split will reduce the number of shares of the Company's common stock outstanding from approximately 44 billion pre-reverse split shares to approximately 4.4 million post-reverse split.

10:48 EDT Endeavour Mining appoints Srinivasan Venkatakrishnan as chair of board - Endeavour Mining is pleased to announce the appointment of Srinivasan Venkatakrishnan as an Independent Non-Executive Director and Chair of the Board and Ian Cockerill as the Senior Independent Non-Executive Director. Both appointments are effective 24 May 2022. Venkat succeeds Michael Beckett who is retiring from the Board after 12 years as Chair. Ian Cockerill rejoins the Endeavour Board as the SID, having served as a Non-Executive Director between September 2013 and March 2019. Venkat was the CEO of the global gold producer, AngloGold Ashanti Limited from 2013 to 2018, and was the Group CEO of the diversified natural resources group Vedanta Resources Limited from 2018 to 2020. Ian Cockerill held executive roles at major international mining companies, including Chief Executive Officer of Gold Fields and Anglo Coal, a subsidiary of Anglo American, and non-executive positions.

10:42 EDT Blue Water Vaccines Inc trading resumes

10:21 EDT Ericsson appoints Scott Dresser as CLO - Ericsson (ERIC) announced the appointment of Scott Dresser to the company's Executive Team as SVP, Chief Legal Officer and Head of Group Function Legal Affairs & Compliance. Scott will join Ericsson on 21 March 2022 and be based in the US. Scott replaces Xavier Dedullen. Dresser joins Ericsson from Veon (VEON), where he has served for eight years as the company's General Counsel.

10:06 EDT FEAM Stock trading resumes

10:00 EDT Direxion Financial Bear 3x falls -6.5% - Direxion Financial Bear 3x is down -6.5%, or -$1.34 to $19.38.

10:00 EDT Modiv falls -12.4% - Modiv is down -12.4%, or -$2.57 to $18.14.

10:00 EDT Full Truck Alliance rises 34.0% - Full Truck Alliance is up 34.0%, or $1.70 to $6.70.

09:57 EDT IXHL Stock trading resumes

09:47 EDT Nine Energy Service falls -5.5% - Nine Energy Service is down -5.5%, or -18c to $3.09.

09:47 EDT Membership Collective falls -7.6% - Membership Collective is down -7.6%, or -53c to $6.39.

09:47 EDT Full Truck Alliance rises 42.0% - Full Truck Alliance is up 42.0%, or $2.10 to $7.10.

09:45 EDT Genenta Science SpA(ADR) trading resumes

09:41 EDT NortonLifeLock now sees Avast deal closing in mid-to-late 2022

09:40 EDT SIFCO Industries trading resumes

09:33 EDT Cardiovascular Systems announces first-in-human experience with Propel device - Cardiovascular Systems announced the first in-human experience with Propel, its first-generation percutaneous ventricular assist device, offering hemodynamic support for patients undergoing high-risk percutaneous coronary interventions. The first series of patients was treated by Dr. David E. Kandzari, MD, FACC, FSCAI, Chief, Piedmont Heart Institute and Cardiovascular Services, Atlanta, Ga., performed in Tbilisi, Georgia. Propel performed as intended, providing uninterrupted hemodynamic support leading to successful revascularization. Propel was used at multiple support levels, with a hemodynamic power output and duration sufficient to maintain the stability of patients during their HR-PCI.

09:32 EDT AKAN Stock trading halted, volatility trading pause

09:30 EDT Genenta Science SpA(ADR) trading halted, volatility trading pause

09:19 EDT Blink Charging awarded $800,000 to deploy DC Fast Chargers by MassDEP - Blink Charging announced that it has been awarded grants from the Massachusetts Department of Environmental Protection, MassDEP, to install 8 dual-port 75-175kW DC fast-charging stations across the state of Massachusetts. The Blink award, totaling $800,000, were awarded under the Massachusetts Electric Vehicle Incentive Program, MassEVIP, which provides grants for installing DC fast-charging stations at strategic locations around the state. "We are thrilled to have been awarded grant funds from MassDEP to continue expanding EV charging access in Massachusetts. The northeast is a rapidly growing EV market. It is one in which we have been successful in being selected for multiple grant and rebate awards," said Brendan Jones, President of Blink Charging. "Continuing to build-out high-density areas and high-traffic corridors will further accelerate consumer adoption of EVs. These new DC fast charging locations will provide Massachusetts residents and travelers with the confidence in the state's charging infrastructure needed to help drive the electric mobility transformation." Blink will install eight dual-port DC fast chargers in strategic locations to further develop the state's charging corridors and convert more drivers to EVs. The chargers will fill existing gaps in EV charging access along major highways and be hosted by familiar consumer brands along Route 90, Route 95, and Route 20.

09:16 EDT Clarus Therapeutics announces initiation of Phase 4 clinical trial of JATENZO - Clarus Therapeutics announced the initiation of screening for the first patient in an investigator-initiated Phase 4 clinical trial designed to evaluate the efficacy and safety of JATENZO oral softgel capsules for the treatment of adult hypogonadal men with chronic kidney disease, CKD. Clarus expects to announce results from the trial in the first half of 2023. "We are excited screening has begun for the first patient in this trial of hypogonadal men with CKD," said Dr. Robert Dudley, President and Chief Executive Officer of Clarus. "Patients with CKD suffer from a myriad of comorbidities, which often include profound reductions in circulating T. Epidemiological data indicate that an estimated two million men with CKD are clinically hypogonadal and thus may benefit from T replacement therapy. This will be the first of several life cycle management studies for JATENZO designed to maximize the potential for treatment of specific patient populations where T deficiency is a component of their compromised health."

09:14 EDT Provectus announces oral presentation on clinical trial of PV-10 - Provectus announced that data from an ongoing clinical trial of investigational cancer immunotherapy PV-10 for the treatment of neuroendocrine tumors, NET, metastatic to the liver, mNET, refractory to somatostatin analogs, SSAs, and peptide receptor radionuclide therapy, PRRT, was presented at the annual conference of the European Neuroendocrine Tumor Society, ENETS, held from March 10-11, 2022 in a hybrid setting in Barcelona, Spain and online. Highlights from the 2022 ENETS Presentation: Patient characteristics: N = 12 patients: 50% male; median age of 66 years. Primary tumor sites: 7 small bowel, 3 pancreas, 1 caecal, and 1 unknown. NET grades: 5 Grade 1 and 7 Grade 2. All patients were refractory to SSA, and 11 received PRRT as part of their prior treatment. All patients had symptomatic, progressive disease. Baseline chromogranin A: median 1,585 microgram/L. PV-10 treatment: 4 patients received more than 1 dose. 8 patients received 1 dose. Safety: All treatment-emergent adverse events were Grade 1 or 2, primarily injection site pain. Single subjects experienced Grade 3 TEAEs of photosensitivity reaction or transaminases increased. Efficacy: Median progression-free survival: 9.4 months. Median overall survival: 22.5 months; 4 patients alive. Subgroup analysis of primary NET histology, pancreas vs intestine: mPFS 2.7 months vs 19.7 months; mOS 11.8 months vs 25.5 months Quality of life: Stable or improved health status and symptoms after 3 months in most patients

09:11 EDT Ibex appoints John Thompson as global head of sales - ibex announced that John Thompson has joined ibex as Global Head of Sales and Janna Normington has joined as Vice President of Utility Solutions. Thompson and Normington bring to ibex deep industry expertise and sales leadership and will be responsible for accelerating sales growth in key markets and building on ibex's 5-year trend of double-digit growth. Thompson is responsible for leading ibex's new logo sales engine and increasing the velocity and size of new business deals. He has spent his career in sales; most recently Thompson led the North American Sales organization at Sitel. Normington will drive ibex's business in the utilities industry and help clients enhance their customer experience and amplify their brand across multiple channels. She previously worked with utilities at Kandela, where she cultivated utility partnerships and increased engagement.

09:10 EDT Sensata collaborates with NIRA Dynamics on TDM sensor - Sensata announced a new collaboration with NIRA Dynamics to deliver a tire Tread Depth Monitoring, or TDM, 'virtual sensor' system for automotive OEMs that optimizes tire health and improves vehicle safety, efficiency and uptime. The TDM solution, powered by NIRA Dynamics' tread wear estimation software, is designed to give vehicle OEMs, drivers and fleets timely alerts when tires have worn to unsafe levels and need servicing.

09:09 EDT IEA selected by Silicon Ranch to construct 70 MW regenerative solar project - Infrastructure and Energy Alternatives, IEA, announced it has been awarded a contract by Silicon Ranch Corporation to construct the Cedar Springs Solar Ranch in Early County, Georgia. The 70-megawatt solar project will provide power to Green Power EMC, the renewable energy supplier for 38 Georgia electric cooperatives. Nashville, Tennessee-based Silicon Ranch is funding the installation of the Cedar Springs Solar Ranch and will own and operate the solar array for the long-term. Silicon Ranch's wholly-owned subsidiary, SR EPC, has awarded the engineering, procurement, and construction contract to IEA Constructors, a wholly-owned subsidiary of IEA. Construction is scheduled to commence by the end of the first quarter of 2022 and the facility is expected to be online by the end of the year. IEA's scope of work includes the installation of owner furnished modules and full balance of system EPC construction, including all civil, mechanical, and electrical work. More than 215,000 First Solar Series 6 modules will be installed across the 1,400-acre site in rural southwest Georgia.

09:07 EDT Founding member banks see Versana syndicated loan platform launch this year - Versana earlier announced its plans to launch an industry-backed syndicated loan platform, which it says will join together banks, institutional lenders and their service providers "to bring transparency, efficiency and velocity to this $5 trillion market." Versana's founding members are J.P. Morgan (JPM), Bank of America (BAC), Citi (C) and Credit Suisse (CS). The Versana platform, which is expected to launch later this year, will "aim to reduce the corporate loan market's operational challenges by digitally capturing agent banks' reference data directly from its source on a real-time basis," the company stated. Industry veteran Cynthia Sachs has been named as CEO and member of the Board of Directors. Sachs has spent the majority of her career as a leveraged finance banker, portfolio manager and trader at Morgan Stanley, Natixis and Bank of America, Versana noted.

09:06 EDT Abercrombie & Fitch launches new activewear sub-brand YPB - Abercrombie & Fitch, a division of Abercrombie & Fitch Co., announces the launch of YPB, an all-new activewear sub-brand. YPB stands for "Your Personal Best" and "aims to empower customers to perform to their highest potential - from sprinting to stretching, lifting to simply life-ing-whatever that may be. The sub-brand features a collection of fashion-forward yet functional activewear and accessories for men and women," the company said. "We've been dedicated to outfitting our millennial consumers for every part of their lives, whether they're traveling, brunching with friends or celebrating a wedding, for example. Being active is another key part of that lifestyle, and now, with the launch of YPB, we can meet those specific needs," said Kristin Scott, Global Brand President at Abercrombie & Fitch Co. "We're laser-focused on listening to our customers, and they were clear: They're looking for fashion-forward activewear that actually performs, looks good and combines quality with value. YPB delivers on all of that, while also providing the comfort and attention to detail that our customers expect from us."

09:06 EDT Toyota Motor North America to invest $27M in TABC - For 50 years, TABC has led the way for Toyota's manufacturing operations in North America. Toyota Motor North America announced a $27M investment in the operation to support an increase in its production capabilities. The investment will equip TABC with the first coil-fed laser blanking line for TMNA, expand blanking capability to include steel and aluminum on the same line and increase capacity to cut 5.6M blanks annually. In addition, these added capabilities will enable TABC to better support Tacoma production at TMNA facilities in Baja, California, and Guanajuato, Mexico. In addition to the new technology and expanded capabilities, the investment will also support the transition of 25 TABC variable employees to permanent positions with Toyota.

09:04 EDT Philips expands medical device cybersecurity imaging portfolio - Royal Philips announced the expansion of its medical device cybersecurity services portfolio at HIMSS22. Philips is introducing Secure Remote Access Management Service, leveraging the broad set of security capabilities enabled by the integration of SecureLink's critical access management and governance technology with Philips Remote Services' secure connectivity framework for technical and clinical support. The services provide benefits for healthcare providers including increased uptime, clinical performance, and advanced security to help protect access to their clinical solutions and medical devices.

09:03 EDT Fulton Financial CEO E. Philip Wenger to retire, Curtis Myers to succeed - Fulton Financial announced that E. Philip Wenger, chairman and chief executive officer, has informed the board that he will retire on December 31 after 43 years of service to the company. After he retires, Wenger will continue to serve as a director of the corporation and its banking subsidiary, Fulton Bank. The corporation's board of directors has named Curtis Myers, currently the corporation's president and COO, to succeed Wenger as chairman, president and chief executive officer, effective January 1, 2023. As he assumes his new role, Myers will continue to serve as the bank's chairman, president and chief executive officer and will continue to serve as a director of the corporation and the bank.

09:02 EDT Izea announces 'all-time record' Q1 Managed Services Bookings - IZEA Worldwide announced that it has been awarded a variety of contracts from both new and existing clients, "propelling IZEA's Managed Services team to its best Q1 bookings in company history," the company said. Managed Services bookings for the quarter have surpassed $10M compared with $6.4M in 2021, an increase of over 50% year over year, with half the month of March remaining. "We broke new Managed Services bookings records every quarter last year, and I am pleased to see the momentum continue in early 2022," said Ted Murphy, IZEA Founder and CEO. "IZEA has been awarded significant contract expansions in Q1. We have also seen strong sales pipeline development and have made many new strategic hires in our sales organization that are not yet fully contributing to bookings. We are seeing success in growing key accounts while venturing into new industries and geographic markets. In a 'US Video Influencer Marketing 2022' report released on March 8, eMarketer predicts that influencer marketing spending in the U.S. will grow by 12% this year - our Managed Services business is currently on pace to well exceed that trajectory and we intend to continue expanding our market share in the U.S. and abroad. Despite global financial and geopolitical challenges, brands are still making major investments into influencer marketing as they know the value of working with creators," Murphy continued. "The month of March has been very strong for us, and we have not directly felt the effects of restrictions or supply-chain shortages with regard to Russia. We had an infinitesimal amount of revenue associated with Russian-based marketers or creators in 2021."

09:02 EDT Elliott supports ongoing board enhancement at NiSource - Elliott Investment Management released the following statement regarding NiSource: "Building on the leadership and Board changes announced recently, we welcome NiSource's appointment of Bill Johnson to the Company's Board. As a former CEO and utility president of Progress Energy, Tennessee Valley Authority and PG&E, Mr. Johnson brings extensive utility oversight experience, demonstrated industry leadership and an ability to evaluate and complete transformational transactions. In conjunction with the company's appointment of a new CEO and two new directors, and the new CEO's announced plans to conduct a full review of the business, NiSource should be well positioned to take actions that will create meaningful shareholder value. As one of NiSource's largest investors, we look forward to our continued dialogue and engagement with the company. We expect that the results of the review will achieve the shareholder value creation that we and our fellow NiSource investors have long anticipated."

08:51 EDT Fat Brands announces three-store development deal in Alaska - FAT Brands announces a new development deal to expand its presence in Alaska with three new locations set to open over the next three and a half years. In partnership with Franchisee Robert Monteith, the development deal will increase the total unit count of Fatburger and Buffalo's Express locations in Alaska to four. In 2020, Monteith introduced the brands to the state, opening in Fairbanks.

08:48 EDT Conduent adds Mental Health Index to HCI platform - Conduent Incorporated announced the addition of the Mental Health Index to its Healthy Communities Institute data and analytics platform. The Mental Health Index visualizes local health and social determinants of health data as a composite measure to guide early interventions, investments, and collaborative partnerships. This index can be used by hospitals and health systems to improve access to care and address gaps in mental health outcomes.

08:47 EDT Omniq awarded $3.5M service project for transport, logistics company - OMNIQ announced that it has awarded an approximately three year $3.5M service project from a worldwide Transport and Logistics multinational leader.

08:41 EDT Definitive Healthcare launches passport analytics suite - Definitive Healthcare announced the general availability of the Passport Analytics Suite, a set of products that helps life science organizations develop, launch and commercialize products more efficiently by delivering data-agnostic analytics on-demand. The Passport Analytics Suite is powered by Analytical Wizards, the company acquired by Definitive Healthcare in February 2022. "We are excited to launch this suite of highly configurable and scalable analytics products built on top of the fabulous technology that we acquired with Analytical Wizards," said Jason Krantz, founder and CEO of Definitive Healthcare. "With these tools, clients can effectively assess and optimize brand performance and dial in the optimal promotional mix. The Passport Analytics Suite helps clients optimize the entire commercialization process, from early-stage business planning needs through post-launch performance acceleration." Comprised of two products - Passport Promotional Analytics and Passport Planning & Performance - the Passport Analytics Suite delivers commercial intelligence around product planning, product performance and marketing optimization. The suite combines a highly configurable front-end application environment with an automated, efficient and scalable back-end cloud platform. The Passport Analytics Suite enables life sciences organizations to establish an analytics on-demand environment at-scale. The suite can integrate internal sales and marketing data with third-party big data on claims, EMR and lab/diagnostics data, as well as publicly available datasets including CMS, clinicaltrials.gov, and CDC epidemiology.

08:39 EDT Taoping smart charging pile service now available in six Chinese communities - Taoping announced that it launched smart charging pile services in six Chinese cities, and is expected to expand to more metropolitan areas in China in the near future. As of March 11, 2022, the installed charging piles have recorded accumulated users of over 20,000 with more than 200,000 valid orders. The six cities with TAOP smart charging piles installed and in operation are Shenzhen, Guangzhou, Quanzhou, Zhenjiang, Nanyang, and Shenyang. "Since the announcement of our strategic cooperation with Zhicheng Chuangtou to expand smart charging pile market in January 2022, we have actively reached out to local communities through our well-established Taoping Alliance network and completed the installation of electric two-wheelers charging piles in residential areas and public places in six cities. The Company expects to expand smart charging pile coverage to 50 cities by the end of 2022," said Jianghuai Lin, Chairman and CEO of TAOP. "We believe this business can empower the transition to a clean energy future and bring new revenue to the Company."

08:37 EDT Quisitive Technology secures bank sponsorship agreement with Peoples Trust - Quisitive Technology Solutions executed a bank sponsorship agreement with Peoples Trust Company, which will allow LedgerPay to process payments in Canada.

08:35 EDT Radius Health appoints Conley as CFO, Clarke as General Counsel - Radius Health (RDUS) announced appointments to new roles on its executive leadership team, effective immediately. Mark Conley has joined Radius as the Company's Chief Financial Officer, CFO. In addition, Kim Clarke has been promoted to the General Counsel position. Both will report to Kelly Martin, the Chief Executive Officer. Conley joins from Kaleido Biosciences (KLDO) where he was most recently the VP of Finance. Kim Clarke joined Radius in 2021 as Assistant General Counsel focusing on part of our asset portfolio.

08:34 EDT Exela appoints Kevin Lathrop as president, Exela Healthcare Solutions - Exela Technologies announced it has hired Kevin Lathrop as President of Exela Healthcare Solutions/ Kevin will lead Exela's healthcare line of business and collaborate closely with leaders across the enterprise to drive Exela's business strategy and value proposition. Kevin will be directly responsible for the growth and performance of HS Most recently, Kevin served as President and Chief Operating Officer for Transaction Data Systems where he was responsible for running the business, growing revenue and profits by double digits .Further, within the Exela HS organization, Chris Spring was recently hired as President of Revenue Cycle Management, and Eokesh Natarajan was promoted to President of Payer Operations.

08:32 EDT II-VI introduces advanced L60 laser tool for precision shaping - II-VI Incorporated announced the introduction of its advanced L60 laser tool for precision shaping of complex profiles in superhard materials including polycrystalline diamond, polycrystalline diamond compact, synthetic diamond, and reaction-bonded ceramics, allowing II-VI to capitalize on emerging industrial applications. II-VI's L60 laser tool relies on a II-VI proprietary patent-pending process to shape profiles in polycrystalline and single-crystal diamond more cost-effectively than existing electrical-discharge machining methods. As the diamond content increases in industrial products, EDM performance decreases due to lower electrical conductivity, and laser processing efficiencies become far more appealing. For PCD parts with ultrathin diamond layers, laser tools such as II-VI's, which achieve surface-lapping precision down to ten microns, are the only option to achieve high processing yields.

08:29 EDT Chipotle tests AI kitchen assistant, Chippy - Chipotle Mexican Grill announced its latest digital innovation, Chippy, an autonomous kitchen assistant that integrates culinary traditions with artificial intelligence to make tortilla chips. Chipotle's culinary and technology teams called on Miso Robotics to customize its latest robotic solution to cook and freshly season Chipotle's delicious tortilla chips. Chippy is currently being tested at the Chipotle Cultivate Center, Chipotle's innovation hub in Irvine, Calif., and will be integrated into a Chipotle restaurant in Southern California later this year. The company is leveraging its stage-gate process to listen, test and learn from crew and guest feedback before deciding on a national implementation strategy.

08:26 EDT Oramed completes patient enrollment in Phase 2 oral insulin NASH trial - Oramed Pharmaceuticals has completed enrollment of all patients in a Phase 2 trial of its oral insulin capsule ORMD-0801 for the treatment of non-alcoholic steatohepatitis - NASH -. Efficacy endpoints including safety and percentage change in liver fat content, liver fibrosis, and liver steatosis from baseline are measured via MRI-PDFF following 12 weeks of dosing. The global market for drugs to treat NASH is expected to reach $84B by 2029.

08:21 EDT Moderna to supply Japan with additional 70M doses of COVID-19 booster vaccine - Moderna announced an agreement with the Ministry of Health, Labour and Welfare of Japan to supply Japan with an additional 70 million doses of Moderna's COVID-19 booster vaccine or an updated booster vaccine candidate, if authorized, for anticipated delivery in the second half of 2022. This agreement is subject to the Ministry securing a budget for the additional supply. In 2022, 93 million doses of Moderna's COVID-19 vaccine are currently contracted for supply to Japan, with the potential for this to increase to 163 million doses with this new agreement.

08:18 EDT Osisko Mining's Windfall drilling intercept high grade in Lynx - Osisko Mining provides new analytical results from the ongoing drill program at its 100% owned Windfall gold project located in the Abitibi greenstone belt, Urban Township, Eeyou Istchee James Bay, Quebec. Significant new analytical results presented below include 50 intercepts in 27 drill holes and 8 wedges. The infill intercepts are located inside defined January 2022 mineral resource estimate blocks. The expansion intercepts are located outside the January 2022 MRE blocks and either expand resource wireframes or are in a defined zone or corridor but do not yet correlate to a specific wireframe. Osisko Chief Executive Officer John Burzynski commented: "The Lynx infill and expansion drill programs continue to impress with respect to both high-grade and width. A third of today's intercepts are greater than an ounce per ton gold and a third are greater than five meters in length. Drilling at Windfall remains focused on Lynx and other strategic areas."

08:17 EDT Starbucks: Schultz volunteering as interim CEO; to receive $1 of compensation

08:14 EDT Healthcare Triangle AWS Cloud Services helps Southeast Iowa Regional Medical - Healthcare Triangle announced it helped a Southeast Iowa Regional Medical Center improve its recovery times by 67%. It strengthened the reliability of its electronic health records, EHR, that support patient life-saving services every day. To improve the reliability and recovery capabilities of the hospital's EHR platform, the provider reached out to Healthcare Triangle. HCTI recommended the use of Elastic Disaster Recovery to set up a secondary site on AWS cloud. Elastic Disaster Recovery is a highly automated service that minimizes downtime and data loss by continuously replicating on-premises and cloud-based applications into AWS, and quickly launching them in the case of an IT disruption. "In addition to better recovery objectives, the healthcare provider has benefitted from reliable, non-disruptive testing and follows the recommended best practice of creating an isolated network within AWS and using Elastic Disaster Recovery to launch a test failover of the MEDITECH application into that isolated environment," the company said.

08:14 EDT Vectrus selected by Department of Defense for 5G smart warehouse development - Vectrus has been selected by the Department of Defense to complete the final phases of application development for a 5G Smart Warehouse at Naval Base Coronado, or NBC. The NBC 5G Smart Warehouse Assessment Team conducted a down select during Phase 1, comparing application solutions from three companies including Vectrus. This effort is part of the DoD's $600M 5G experimentation and testing initiative, originally awarded in 2020.

08:12 EDT MarketAxess launches MKTX U.S. Investment Grade 400 Corporate Bond Index - MarketAxess Holdings announced the launch of the MKTX U.S. Investment Grade 400 Corporate Bond Index. The launch of MarketAxess' first tradable index underscores the company's long-term commitment to creating innovative and actionable data solutions in the fixed income market. The MKTX 400 Index, administered by MarketAxess Technologies Inc., tracks the performance of 400 U.S. dollar denominated investment grade corporate bonds with higher-than-average liquidity relative to the broader U.S. corporate bond market. Powered by MarketAxess' proprietary liquidity and pricing data - Relative Liquidity Score and Composite+ pricing engine - the Index combines actionable liquidity with broad market exposure.

08:11 EDT Palisade Bio announces analysis of studies LBS-IST-POI-101, LBS-POI-201-CN - Palisade Bio announced data from a Pooled-Analysis of Studies LBS-IST-POI-101 and LBS-POI-201-CN. These data are featured today at the Next Big Thing session of the Society of American Gastrointestinal and Endoscopic Surgeons, SAGES, 2022 Annual Meeting, being held in Denver, March 16-19. Highlights are: LB1148 reduced incidence of adhesions by 72% in patients undergoing bowel resection; LB1148 reduced extent and severity of adhesions by 93% in patients undergoing bowel resection; The incidence of adhesions in the placebo group was similar to the published incidence; 100% of placebo-treated subjects underwent a laparoscopic procedure, and 8 of 9 had greater than or equal to 1 adhesions; 75% of the 8 LB1148-treated subjects underwent a laparoscopic procedure, and 2 of 6 had greater than or equal to 1 adhesions; 25% of the 8 LB1148-treated subjects underwent a laparotomy, and neither formed adhesions; and No drug-related serious adverse events occurred in the trials. Studies LBS-IST-POI-101 and LBS-POI-201-CN assessed the efficacy of LB1148 to reduce the formation of adhesions in subjects undergoing abdominal surgery. Study LBS-IST-POI-101 was a Phase 1, single-center, open-label, study enrolling 11 subjects undergoing GI surgery. The PROFILE-CN study was a 120-subject Phase 2, randomized, double-blind, placebo-controlled study conducted in collaboration with co-development partner, Newsoara Biopharma to evaluate LB1148 for return of GI function in subjects undergoing planned bowel resection surgery. In both trials, a subset of subjects went on to have a second surgery. In these subjects, adhesions were assessed and quantified at the time of surgical closure during the initial surgery and at the time of opening at the subsequent surgical procedure.

08:11 EDT WeWork expands to Boston, Chicago, Los Angeles, D.C., following launch in NYC - Following a launch in NYC, WeWork Growth Campus is expanding to Boston, Chicago, Los Angeles, and Washington, D.C. WeWork is expanding its WeWork Growth Campus program nationally and committing an additional $35 million in space for startups and nonprofits in four cities across the country. As part of this national expansion, WeWork is committing $4.8M in space in Boston; $8.8M in space in Chicago, $5.2M in space in Los Angeles and $16.3M in space in Washington, D.C. In addition to the 11 existing WeWork Growth Campus locations in New York City, WeWork Growth Campus members will now will now have the choice of space in more than 800 offices in 13 additional locations across the country: "While the pandemic has challenged businesses across all sectors, we've also seen entrepreneurship rally in the face of adversity across the country, as Americans filed for more new businesses - 5.4 million in 2021 - than in any other year on record," said Melinda Holland, President and COO of The Americas at WeWork. "As 2022 looks to be another record year for new businesses, we couldn't be more thrilled to expand WeWork Growth Campus across the country and do our part to help support American innovation, entrepreneurship and service."

08:09 EDT Clovis, Evergreen enter development agreement for actinium-225-labeled-FAP-2286 - Clovis announced the initiation of a development, manufacturing, and services agreement with Evergreen Theragnostics to develop actinium-225-labeled-FAP-2286. Under the agreement, Clovis and Evergreen intend to develop radiolabeling chemistry and analytical methods for use in potential future pre-clinical and clinical studies. Under the terms of the agreement, Evergreen will develop 225Ac-FAP-2286 at its facility in Springfield, New Jersey. The facility was purpose-built to develop and manufacture a variety of therapeutic radiopharmaceuticals, including those based on alpha-emitting isotopes such as 225Ac, from early development to commercial scale manufacturing.

08:08 EDT Mizuho Americas appoints Dominic Konstam as head of macro strategy - Mizuho Americas (MFG) announced the hiring of Dominic Konstam as Managing Director, Head of Macro Strategy within the Interest Rate Products business, a key part of the firm's Fixed Income Division. Konstam recently served as Co-Head of Rates Research at Citibank (C).

08:07 EDT NetApp, Cisco expand partnership with new FlexPod XCS for hybrid cloud usage - NetApp (NTAP) together with Cisco (CSCO) announced the evolution of FlexPod with the introduction of FlexPod XCS, providing one automated platform for modern applications, data and hybrid cloud services. FlexPod is composed of pre-validated storage, networking, server technologies from Cisco and NetApp. The new FlexPod XCS platform is designed to accelerate the delivery of modern applications and data in a hybrid cloud environment. FlexPod XCS is the first and only hybrid cloud solution natively integrated across all three major public cloud providers. Additionally, organizations will have the option to use FlexPod-as-a-Service, a pay-as-you-grow pricing model for financial and operational flexibility. "For years, FlexPod has been helping Presidio customers increase app performance, save software Capex, an decrease unplanned downtime incidents," said Raphael Meyerowitz, vice president, Engineering at Presidio. "With FlexPod XCS, NetApp and Cisco are providing more flexibility, accessibility and scalability to our customers to deliver a seamless hybrid cloud experience." "It is great seeing Cisco and NetApp launching FlexPod XCS together in this hybrid cloud era," said Jeffrey den Oudsten, Chief Technology Officer at Conscia Netherlands. "Standardization on FlexPod XCS brings rich technologies and huge benefits for us and our customers in various ways, with ability to deliver one point for billing, ordering, support and validated designs. Conscia is determined to facilitate the best hybrid cloud infrastructure for its customers, and together with Cisco and NetApp, we have the best-in-class technology partners helping us to deliver on that promise." FlexPod XCS simplifies hybrid cloud operations by increasing accessibility and scalability, extending the infrastructure from an on-premises and edge standard to the hybrid cloud. This new offering lays the groundwork for continued joint innovation that will bring new solutions to market for hybrid cloud, containers, and modern workloads.

08:07 EDT Sema4 Holdings announces nationwide expansion of disparity study - Sema4 announced the nationwide expansion of its disparities in cancer care study. The study, launched in 2021, enables access to comprehensive genetic and genomic testing for advanced cancer patients in underserved communities. It will also create one of the most diverse clinical-genomic datasets to help resolve racial, ethnic, and socioeconomic disparities in clinical trials, research, and therapeutics. William Oh, MD, Chief Medical Science Officer at Sema4, will discuss the study at the Community Oncology Alliance's upcoming conference in Florida on March 18th. The REsearch to advance PREciSion medicine and health Equity in oNcology Treatment study, which is already enrolling patients at five locations across two sites, will run nationally in collaboration with community oncologists caring for patients with advanced cancer in diverse and traditionally understudied and underserved populations. Disparities in healthcare access and a lack of diversity in clinical trials have led to significant disparities in the standard of oncology care. For example, Black and African American individuals have higher mortality rates than all other racial and ethnic groups for many cancer types. Sema4's study aims to better understand the factors contributing to cancer care disparities in underserved populations, including socioeconomic and genetic considerations, by creating a diverse and comprehensive patient registry and biobank. REPRESENT is a prospective observational study that will enroll up to 5,000 advanced-stage cancer patients. Two sites are currently operating in North and South Carolina, with 226 patients enrolled, and nine other sites are in discussion. As part of the study's criteria, at least 30% of enrolled patients at each site must be part of an underserved minority community. Data and samples gathered from consenting patients will be used to establish a clinical-genomic patient registry and biobank. Registries are used to collect standardized patient information. Similarly, biobanks, which are essential resources in the development of targeted therapies in oncology, contain clinical data, biological specimens, and additional associated information for future use in research and clinical testing.

08:06 EDT Werewolf Therapeutics announces publication of data on WTX-124 - Werewolf Therapeutics announced the publication in Cancer Immunology Research of preclinical data for its lead molecule WTX-124, a systemically delivered Interleukin-2 INDUKINE molecule. The article, entitled "Discovery of a Conditionally Activated Interleukin-2 that Promotes Anti-tumor Immunity and Induces Tumor Regression," includes preclinical data that demonstrate the efficacy of the design of WTX-124 in delivering IL-2 selectively to the tumor microenvironment where it stimulates a potent anti-tumor immune response. "IL-2 is a cytokine that has delivered lasting therapeutic benefit through activation of anti-tumor immunity. To date, the clinical utility of systemically delivered recombinant human IL-2 has been hindered by serious side effects in normal tissues and poor pharmaceutical properties, including a short circulating half-life, which limits the ability to reach efficacious exposures in tumors," said Cynthia Seidel-Dugan, Ph.D., Chief Scientific Officer of Werewolf and one of the article's authors. "Our published preclinical data show that WTX-124 has an improved therapeutic window compared to recombinant human IL-2 in mouse models and the potential to minimize the toxicity associated with systemic IL-2 administration." Other key findings and data outlined in the article include: WTX-124 treatment triggers the infiltration and activation of T cells and natural killer cells in tumors and markedly shifts the immune activation profile of the tumor microenvironment; WTX-124 treatment of tumor-bearing mice results in immunological memory; WTX-124 has an improved therapeutic window compared to recombinant human IL-2 in the mouse; WTX-124 is stable in human serum and is processed by the majority of primary human tumor specimens tested. The Company expects to file an Investigational New Drug Application for WTX-124 in the first half of 2022.

08:04 EDT Arko Corp.'s GPM appoints Ruth Ann Lilly as SVP, marketing, merchandising - GPM Investments announced its promotion of Ruth Ann Lilly to Senior Vice President of Marketing and Merchandising. Lilly is a seasoned executive with 31 years' experience in the convenience store industry. She joined GPM in 2017 as Senior Category Manager of tobacco.

08:03 EDT Sono-Tek expects to achieve record revenue growth for FY23 - Based on current backlog, shipments, and proposal activity, Sono-Tek expects to report a greater than 15% increase in revenue for the first quarter of FY2023, ending May 31, 2022, when compared to the first quarter of last fiscal year. Management does not typically forecast results for the full fiscal year at this time, but the strong FY2022 year-end backlog supports the projection that Sono-Tek will again achieve record revenue growth for FY2023, ending February 28, 2023.

08:02 EDT Starbucks board forms working commitee to oversee CEO search process

08:02 EDT Starbucks sees selecting permanent CEO by the fall

08:01 EDT Starbucks CEO Kevin Johnson to retire, Howard Schultz named interim CEO

07:50 EDT NLS Pharmaceutics announces interim top-line data for Quilience - NLS Pharmaceutics announces interim top-line data from its Phase 2a clinical trial evaluating its lead product candidate, Quilience, in the treatment of narcolepsy. The data are being presented and discussed today during a symposium sponsored by NLS at the World Sleep Congress, being held in Rome, Italy. Of the 60 patients targeted for full enrollment in the U.S. Phase 2a trial, 27 were randomized and completed the study for the interim analysis. The interim analysis database included 13 patients on treatment and 14 patients on placebo, with balanced mean baseline Epworth Sleepiness Scale scores. All patients enrolled in the interim analysis were utilizing combination therapy before the trial's wash out period, with the majority of participants on stimulant or wake-promoting agents to treat their excessive daytime sleepiness. Approximately one-third of patients enrolled in the interim analysis were diagnosed with narcolepsy type 1 and suffer from both EDS and cataplexy symptoms. Eligible NT1 patients must have moderate to severe disease according to the study protocol - defined as having more than 3-4 cataplexy attacks per week. Study participants on treatment are required to undergo a 1-2-week wash out period. After the wash out period, participants are randomized to receive either once-daily treatment with Mazindol ER 2mg for week 1 and 3mg for weeks 2-4, or placebo for 4 weeks. For EDS, the trial's primary endpoint, patients on Mazindol ER exhibited a mean decrease of 7.3 points on the ESS compared to a 3.0 point decrease for patients on placebo. Patients on Mazindol ER showed a mean 39% improvement on ESS from baseline. The placebo-adjusted reduction of 4.3 points is deemed to be clinically meaningful and is competitive compared to current narcolepsy treatments, despite the short duration and relatively small number of patients in the interim analysis. These interim results confirm the statistical power of the ongoing Phase 2a trial, which will continue as planned. To date, Mazindol ER was generally safe and well-tolerated in the current Phase 2a trial, and the interim data are consistent with prior mazindol studies, including the Company's clinical trials evaluating treatment of attention deficit hyperactive disorder. No patients dropped out of the study due to safety or efficacy concerns, and only one patient in the interim analysis discontinued the study for personal reasons. This compares favorably to other clinical trials for narcolepsy treatments, for which study discontinuation rates can be as high as 15% or more for efficacy and safety reasons. No serious adverse events were reported in the interim analysis and all reported adverse events were mild or moderate and resolved immediately with no intervention required. Study NLS-1022 enables patients completing the randomized controlled trial to access treatment with Mazindol ER without any background stimulant and/or anti-cataplexy treatment for up to 6 months. As of the data collection date for the Phase 2a interim analysis, 82% of patients who completed the randomized controlled study elected to participate in the OLE study. A majority of those patients remain in the OLE study and on treatment with Mazindol ER, including participants suffering from NT1, with one patient on single agent therapy for over 3 months.

07:44 EDT AC Immune reports first live images of a-syn in human brain - AC Immune announced the first non-invasive images of pathological alpha-synuclein in human brain and presented positive clinical proof-of-concept data for an a-syn positron emission tomography tracer as an imaging agent to identify MSA patients. Prof. Andrea Pfeifer, CEO of AC Immune SA, commented: "This first clinical validation for an a-syn PET tracer is a transformative step towards achieving our vision for developing precision medicines to treat neurodegenerative diseases. It was made possible by the close collaboration between AC Immune, Skundefinedne University Hospital, Lund University, and the MJFF. We look forward to continuing the collaboration to expand on these results in MSA and in other a-syn indications, such as Parkinson's disease." The data will be presented in more detail on Friday in two presentations at the peer-reviewed scientific conference. Derived from AC Immune's Morphomer technology platform, ACI-12589 showed target engagement in vivo in alpha-synucleinopathies with a pharmacokinetic and safety profile suitable for further development as a human brain PET imaging agent. The trial showed that non-invasive PET brain imaging with ACI-12589 successfully differentiated MSA from other types of a-synucleinopathies, like Parkinson's disease and Lewy Body Dementia, as well as from healthy volunteers.

07:42 EDT Membership Collective says it is confident in revenue recovery - The company said, "We remain confident about the overall recovery of our MCG Group revenues given the positive momentum of Q4'21 carrying through into Q1'22. Our February 2022 revenues in our UK and US Houses and Restaurants, performed 15% and 3% above the comparative 2019 pre-pandemic levels, respectively. Total MCG membership increased by a further 6% in the first two months of the current quarter. Together with our high level of member retention, record waitlist numbers and growth from new Houses, membership continues to be a very valuable recurring revenue stream. We have accelerated our pipeline for site openings in 2022 to nine Soho Houses covering four new Countries. In the first quarter of 2022 we will have opened two new Soho Houses in Nashville and Brighton. This will be followed in April by Holloway House in West Hollywood. From fiscal 2023 onwards, we now aim to open 8-10 new Soho Houses per annum. With the increased Houses in our pipeline combined with the unprecedented demand for our memberships we feel confident in exceeding our membership goals this year. We remain cautious about the emergence of any future COVID-19 variants, along with continued inflationary pressures, particularly in energy supply. However, we have several cost control programs in progress to counter some of these pressures. Notwithstanding these headwinds we expect to deliver sustained margin growth within the short term and beyond."

07:41 EDT Sonnet BioTherapeutics announces FDA clearance of IND for SON-1010 - Sonnet BioTherapeutics announced that the U.S. Food and Drug Administration has cleared the Company's Investigational New Drug application for SON-1010, a proprietary version of Interleukin 12 configured using Sonnet's Fully Human Albumin Binding technology. This will allow Sonnet to initiate its First-in-Human Phase 1 trial in adult oncology patients in the second quarter of 2022. The planned Phase 1 trial will be a multiple ascending dose study designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of SON-1010 in adult patients with advanced solid tumors. The study, utilizing a standard 3+3 oncology design in at least 5 cohorts, will establish the maximum tolerated dose and recommended Phase 2 dose using monthly subcutaneous injections of SON-1010. The primary endpoint will assess the safety and tolerability of SON-1010, with key secondary endpoints planned to measure PK, PD, immunogenicity, and anti-tumor activity.

07:39 EDT nCino announces HVB live on nCino's Bank Operating System - nCino announced that Huntingdon Valley Bank, HVB, is live on nCino's Commercial Pricing and Profitability on the nCino Bank Operating System. "Powered by nCino IQ, nCino's Commercial Pricing and Profitability solution provides increased efficiency, transparency and real-time data insights for the institution's business banking and commercial lending divisions," the company said. "Providing financial institutions with solutions that can connect data and intelligence seamlessly to align strategy with execution is essential to transforming our customers' ability to provide a premier experience for their clients. HVB has embraced our single platform infrastructure for quite some time, and this is just the next step on their digital transformation journey," said Will Cameron, Senior Vice President of Community and Regional Banking at nCino. "We're excited for our continued partnership with HVB and providing them a single platform that can capture deeper customer insights to provide better decisions for their clients."

07:39 EDT Land's End drops 10% to $14.25 after Q4 results, FY22 guidance miss estimates

07:34 EDT KemPharm earns $1.975M fee from Corium following FDA approval of ADLARITY - KemPharm announced that the Company has earned a $1.975M fee from Corium, a portfolio company of Gurnet Point Capital, following the approval of Corium's product ADLARITY by the U.S. Food and Drug Administration, FDA, on March 11, 2022. ADLARITY is an innovative new treatment option for patients with mild, moderate, or severe dementia of the Alzheimer's type. KemPharm is due to receive the fee, within thirty calendar days following FDA approval of ADLARITY, pursuant to a master development services agreement entered into with Corium in July 2020, under which KemPharm provided development and regulatory assistance related to Corium's resubmission of its New Drug Application for ADLARITY. "We are pleased to have been able to assist Corium in obtaining FDA approval of ADLARITY, and we congratulate them on this significant achievement," said Travis Mickle, Ph.D., President and CEO of KemPharm. "Looking forward, we expect to file our IND for KP1077 in the second quarter of this year as we continue to pursue our strategy of building a growing pipeline of product candidates for the treatment of sleep disorders and other orphan/rare diseases in CNS-related therapeutic areas."

07:33 EDT The Very Good Food Company lowering production, headcount - The Very Good Food Company announced that the company is temporarily lowering production throughput and headcount to manage inventory levels, and implementing initiatives such as pausing non-critical capital expenditures and lowering SG&A spending, to manage both short and long-term liquidity and to establish a path towards profitability. "As a result of the supply chain environment, we undertook certain stock safety measures to protect against stock outages," stated Mitchell Scott, CEO, and founder of VERY GOOD. "This, in conjunction with retailer reset timing delays, has resulted in inventory being at levels that require us to lower production at some of our locations. This decision was made after a long and careful review of our options and will impact some of our production team members. We are thankful for their contributions. VERY GOOD is taking this opportunity to implement additional cost improvement measures as it transitions from a focus on top line growth, to a focus of balancing top line growth and profitability. As part of this shift, VERY GOOD expects to further right-size its workforce across multiple business functions as it streamlines operations. VERY GOOD is currently reviewing its 'go-to market' channels. Digital marketing costs to acquire new customers have increased over the past year, largely related to structural changes of the largest digital and social platforms. This challenge has required us to review our online strategy and marketing expenditures to optimize our return on investment. As such, we expect our growth will slow down in the near-term in this channel. VERY GOOD will continue to focus on the wholesale and food service channels, particularly in the US, which the company views as critical to realizing its vision to scale. VERY GOOD experienced a greater than expected cash burn in the last several months as the company scaled its operations to meet its growth targets, which has reduced its cash position and has strained its short-term liquidity. The initiatives VERY GOOD is implementing, including pausing non-critical capex and significantly lowering SG&A spending, will allow the Company to manage both short-term and long-term liquidity and increase its cash runway. Management will continue to evaluate ways to increase its cash position and/or seek additional financings with as little dilution as possible. We thank our team members for their focus and dedication throughout this process."

07:29 EDT Telos to delay filing of annual report on Form 10-K - The Company will not file its Annual Report on Form 10-K on March 16, 2022, as previously expected and as reported on its recently-filed Form 12b-25. The principal reasons for the delay in completing our year-end closing and financial reporting process are primarily due to delays in completing our assessment of the effectiveness of our internal control over financial reporting. As a result of the foregoing, the Company's independent registered public accounting firm has not yet completed its audits of the Company's financial statements and internal control over financial reporting as of December 31, 2021.

07:22 EDT Afya receives medical school authorizations - Afya announced that the Secretary of Regulation and Supervision of Higher Education of the Ministry of Education, or MEC, authorized the operations of the medical schools in Braganca, in the State of Para, and Manacapuru, in the State of Amazonas, both under Mais Medicos II program. Afya reaches its fifth and sixth authorized schools operating under the Mais Medicos II program with the authorizations. Each medical school will contribute with 50 seats and with that, Afya will reach 2.681 operating seats out of 2.731 approved seats.

07:22 EDT AIM ImmunoTech receives IND clearance to advance Phase 2 study of Ampligen - AIM ImmunoTech announced it has received notification from the U.S. Food and Drug Administration, FDA, that the FDA's Clinical Hold on AIM's investigational new drug, IND, application for a Phase 2 study of Ampligen as a therapy for locally advanced pancreatic cancer, APM-270, has been lifted and the Company may proceed with the study. "Based on the data we've seen to date, we believe Ampligen has the potential to offer an important treatment option to patients living with pancreatic cancer. This is a significant milestone for the Company and further positive Phase 2 confirmation of these results would demonstrate the potential of Ampligen as an effective therapy option. We are incredibly pleased and grateful to the FDA for its authorization, which enables us to proceed with further clinical evaluation. Our team is focused on commencing our Phase 2 study which we believe brings us another step closer to providing a potentially effective therapy after systemic chemotherapy in patients with advanced pancreatic cancer," commented Thomas Equels, Chief Executive Officer of AIM. The AMP-270 clinical trial is planned to be a randomized, open-label, controlled, parallel-arm study with the primary objective of comparing the efficacy of Ampligen versus a no treatment control group following FOLFIRINOX for subjects with locally advanced pancreatic adenocarcinoma. Secondary objectives include comparing safety and tolerability.

07:21 EDT StorageVault Canada announces normal course issuer bids - STORAGEVAULT CANADA is pleased to announce that it has received conditional acceptance from the Toronto Stock Exchange to conduct a Normal Course Issuer Bid to purchase for cancellation, during the 12-month period starting March 18, 2022: up to 18,931,054 of the outstanding common shares of the Corporation, representing 5% of the 378,621,086 Common Shares outstanding; outstanding 5.75% senior unsecured hybrid debentures of the Corporation issued in July 2020 and due on January 31, 2026 in the aggregate principal amount of $3,750,000, representing 5% of the currently outstanding $75,000,000 aggregate principal amount of 2020 Debentures; and outstanding 5.50% senior unsecured hybrid debentures of the Corporation issued in July 2021 and due on September 30, 2026 in the aggregate principal amount of $2,875,000, representing 5% of the currently outstanding $57,500,000 aggregate principal amount of 2021 Debentures. Each NCIB will end on March 17, 2023, unless the maximum amount of Common Shares or Debentures, as applicable, is purchased before then or StorageVault provides earlier notice of termination. StorageVault will not acquire through the facilities of the TSX more than 62,807 Common Shares, $11,700 aggregate principal amount of 2020 Debentures or $20,400 aggregate principal amount 2021 Debentures, during a trading day, being 25% of the average daily trading volume of the Common Shares (251,231), 2020 Debentures ($46,800) and 2021 Debentures ($81,600), respectively, on the TSX from January 26, 2022 until February 28, 2022, subject to certain prescribed exceptions. The stock symbol on the TSX for the Common Shares, 2020 Debentures and 2021 Debentures is SVI, SVI.DB and SVI.DB.B, respectively. The purchase and payment for the Common Shares and Debentures will be made by StorageVault through the facilities of the TSX or alternative trading systems. National Bank Financial Inc. has been selected as StorageVault's agent for the NCIB. The price paid for the Common Shares or Debentures, as applicable, will be, subject to NCIB pricing rules contained in securities laws, the prevailing market price of such Common Shares or Debentures, as applicable, on the TSX at the time of such purchase. StorageVault intends to fund the purchases out of available cash. StorageVault believes that the market price of its Common Shares and Debentures may not reflect their underlying value and the Board of Directors has authorized this initiative because, in the Board's opinion, the proposed purchase of Common Shares and Debentures pursuant to the NCIB constitutes an appropriate use of StorageVault's funds, and the repurchase of its Common Shares and Debentures is one way of creating securityholder value. To the knowledge of StorageVault, no director, senior officer or other insider of StorageVault currently intends to sell any Common Shares or Debentures under the NCIB. However, sales by such persons through the facilities of the TSX may occur if the personal circumstances of any such person changes or any such person makes a decision unrelated to these NCIB purchases. The benefits to any such person whose Common Shares or Debentures are purchased would be the same as the benefits available to all other holders whose Common Shares or Debentures are purchased. StorageVault conducted a previous NCIB for up to 18,312,741 Common Shares and $3,750,000 2020 Debentures through the facilities of the TSX Venture Exchange, which NCIB ended on January 24, 2022. Pursuant to the previous Common Share NCIB, StorageVault purchased an aggregate of 875,615 Common Shares, at a volume weighted average price of $5.11 per Common Share, and no 2020 Debentures were purchased.

07:19 EDT Howard Hughes appoints Jesse Carrillo as Chief Innovation Officer - Howard Hughes has named Jesse Carrillo the company's Chief Innovation Officer, effective March 16. Carrillo will oversee the strategy and operation of the company's innovation and technology platforms across HHC's national portfolio of large-scale master planned communities and mixed-use properties. Prior to joining HHC, Carrillo served as Chief Information Officer of Hines. He joined the firm in 1994 and served in various technology roles before becoming the company's Chief Technology Officer in 2007 and then its Chief Information Officer in 2009.

07:18 EDT CareDx to hold virtual "Xenotransplantation Innovation Day" - CareDx announced that it will hold a virtual "Xenotransplantation Innovation Day" featuring a leading panel of transplant experts who will share the latest advancements in xenotransplantation after genetically modified pig kidneys and, separately, a pig heart were recently successfully transplanted, two medical firsts. CareDx's "Xenotransplantation Innovation Day" will be held on March 22, 2022 from 9:00am to 10:00am PDT / 12:00noon to 1:00pm EDT. The presentations and panel discussions will be held in a virtual format to enable a wide audience to learn from these experts. The symposium will include an update from the University of Maryland School of Medicine on the world's first successful living pig-to-human heart transplant, an update from NYU Langone Health on the world's first transplant of a gene-edited pig kidney, as well as recent developments of clinical-grade, human-compatible organs, and cells from eGenesis and Miromatrix.

07:16 EDT Xeris Biopharma announces Gvoke Kit available by prescription - Xeris Biopharma announced that Gvoke Kit is now available by prescription. Gvoke Kit contains one single-dose sterile syringe with markings for 0.1 mL and 0.2 mL, and one single-dose vial containing 0.2 mL of solution.

07:14 EDT Orthofixs gets FDA clearance, 1st patient cases with TrueLok system - Orthofix Medical announced the U.S. Food and Drug Administration 510k clearance and the first patient cases with the TrueLok EVO Ring Fixation System. Designed for complex limb reconstruction and deformity correction procedures, the TrueLok EVO system is the only circular fixator on the market that features both radiolucent rings and struts to enable clear radiographic visualization. This innovative design allows physicians to better assess bone anatomy both during surgery and post-operative care. The TrueLok EVO system is also the first circular external fixation kit available as a preassembled frame in ready-to-use single use sterile packaging, allowing for ease of application and potential time-saving during surgery, particularly when treating post-traumatic injuries.

07:12 EDT Amicus announces long-term data from Phase 1/2 study of AT-GAA - Amicus Therapeutics announced additional positive results from a global Phase 1/2 clinical study, ATB200-02, to investigate AT-GAA in adult patients with Pompe disease, an inherited lysosomal storage disorder caused by an enzyme deficiency that leads to accumulation of glycogen in cells. Study participants treated with AT-GAA for up to 36 months showed persistent and durable effects on six-minute walk test distance and other measures of motor function and muscle strength, stability or increases in forced vital capacity, and reductions in biomarkers of muscle damage and disease substrate. These clinical results are being featured at the 2022 MDA Clinical & Scientific Conference in an oral platform presentation on Wednesday, March 16, 2022. Long-term data from the Phase 3 PROPEL open-label extension study is expected to be presented later this year. ATB200-02 Study Data Highlights in ERT-Experienced and ERT-Naive Patients Out to Month 36, Cohorts 1 - 4: Functional Outcomes: Amongst ERT-naive patients, 6MWT distance increased in 6/6, 5/5, and 4/5 patients at months 12, 24, and 36, respectively. The ERT-naive patients showed mean increases of 57 meters at month 12, 61 meters at month 24, and 44 meters at month 36. 6MWT distance increased in 13/16, 8/10, and 6/8 ERT-experienced patients at months 12, 24, and 36, respectively. The ERT-experienced patients showed mean increases of 34 meters at month 12, 21 meters at month 24, and 48 meters at month 36. Muscle Strength: Ambulatory and non-ambulatory patients, including ERT-experienced and ERT-naive, showed improvements in strength testing as assessed by manual muscle testing (MMT) and improvements were maintained out to 36 months. Pulmonary Function: Pulmonary function improved in ERT-naive patients and was generally stable in ERT-experienced patients. In ERT-naive patients, mean change in percent predicted forced vital capacity, one of the main measures of pulmonary function in Pompe disease, was +4.5% at month 12, +6.8% at month 24, and +6.2% at month 36. In ERT-experienced patients, mean change in % predicted FVC was -1.3% at month 12, -0.9% at month 24, and -0.4% at month 36. Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics in Cohorts 1-4: To date, adverse events have been generally mild and transient; The clinical pharmacokinetic profile has been consistent with previously reported data; Persistent and durable reductions in key biomarkers of muscle damage and disease substrate across all patient cohorts out to month 36 continue to suggest a positive effect on muscle tissue.

07:09 EDT Gran Colombia Gold announces drill results from Segovia operations - GCM Mining announced multiple high-grade intercepts at its Segovia Operations from the final 39 diamond drill holes, totaling 9,158 meters, of its 2021 in-mine and near-mine drilling programs, as well as the final 27 diamond drill holes, totaling 7,125 meters, from its 2021 brownfield drilling programs. The Company also announced the assay results from 2 additional kick-off diamond drill holes, totaling 1,140 meters, from the ongoing directional drilling at the El Silencio Deep Zone. Significant high-grade intercepts from the latest drill results include: In-mine and near-mine drilling: Sandra K: 40.39 g/t Au and 42.4 g/t Ag over 0.41 meters on the Sandra K Techo FW Vein; Sandra K: 159.88 g/t Au and 248.0 g/t Ag over 0.30 meters on the Sandra K Techo Vein; El Silencio: 38.41 g/t Au and 28.6 g/t Ag over 0.68 meters on the Manto Vein; El Silencio: 236.44 g/t Au and 123.6 g/t Ag over 0.60 meters on the Nacional Vein; Carla: 254.30 g/t Au and 316.7 g/t Ag over 0.45 meters on the La Gran Colombia Vein. Brownfield drilling Marmajito: 131.10 g/t Au and 294.3 g/t Ag over 0.32 meters on the Marmajito Vein. La Guarida-Cristales Trend: 56.88 g/t Au and 41.0 g/t Ag over 0.39 meters on the La Guarida-Cristales Trend. Serafino Iacono, Executive Chairman of GCM Mining, commented, "We completed a very robust exploration campaign at our Segovia Operations in 2021 with a total of approximately 97,000 meters completed in 444 diamond drill holes at our producing mines and our high-priority brownfield targets. These drill results will be incorporated in the annual mineral reserve and resource updates that are expected to be announced later this month. Our Segovia Operations continue to demonstrate their prowess as a world-class system, both in terms of its size and high grades, as shown by the continued outstanding results from the 2021 drilling programs. The team's exploration model and understanding of the local vein systems led to the discovery of the 1040 Vein at the El Silencio Mine in 2021 which has the potential to add substantial resources and increase the mine life for this operation. Drilling from surface at the Sandra K Mine has proven the down-plunge extension of the main ore-shoots to well below the deepest level of the mine, as well as a further strike extension of the main vein system to the north by 150 meters. In addition, brownfield drilling on the Marmajito Vein has shown multiple high-grade intersections, which reinforce the exploitation potential of this vein by taking advantage of the proximity of the Providencia Mine's infrastructure. For 2022, we have committed to contining our exploration campaign at Segovia with another 91,000 meters of drilling at our producing mines and high-priority brownfield targets." The 2021 in-mine and near-mine infill and step-out drilling programs commenced in January 2021 and focused on replacing the 2021 mine production and on organic growth through resource and reserve expansion at the Company's core operating mines. GCM Mining completed a total of 184 drill holes in 2021 totaling 47,735 meters which represented about 119% of plan. The in-mine and near-mine drilling campaign was complemented by another 196 diamond drill holes totaling 33,471 meters that were completed in 2021 in an ongoing underground in-fill drilling campaign carried out by the Company's Mine Geology Department, primarily at the El Silencio Mine, which focused on resource definition within the underground mine developments. The 2021 brownfield drilling campaign, which focused on exploration for new resources at the brownfield exploration targets on the 24 veins within the Segovia mining title that are not currently in production, commenced in late 2020 at the Vera Project. The 2021 brownfield exploration drilling campaign was finalized at the end of December 2021 with a total of 64 drill holes totaling 15,924 meters, about 20% less than planned mainly due to the lengthy administrative processes involved to obtain permission to access the land where the drilling platforms were built. GCM Mining's 2022 diamond drilling campaign will comprise approximately 91,000 meters with up to 52,000 meters of in-mine and near-mine drilling and 15,000 meters of underground in-fill drilling at its four producing mines together with 24,000 meters of brownfield drilling at its high-priority targets within the other 24 known veins it is not currently mining in its Segovia mining title.

07:08 EDT TransUnion enters software partnership with Funnel Leasing - Funnel Leasing announced a new partnership with TransUnion. The new integration will empower renters with an application experience and assist operators with making better screening decisions. TransUnion's rental screening solutions ResidentScore and ResidentID products are integrated into the Funnel platform, enabling a suite of reporting functionality and improvements to collected data capabilities.

07:07 EDT Talos Energy executes Texas CCS site lease, enters strategic alliance with Core Lab - Talos Energy (TALO) announced that Bayou Bend, Talos's venture with Carbonvert, executed definitive lease documentation with the Texas General Land Office - GLO -, formalizing the previously announced carbon capture and sequestration - CCS - site located offshore Jefferson County, Texas, near the Beaumont and Port Arthur, Texas industrial corridor. Talos separately established a CCS strategic alliance with Core Laboratories (CLB) to provide technical evaluation and assurance services for CCS subsurface analysis, including the company's upcoming 2022 stratigraphic evaluation wells. On March 11, the Venture jointly executed lease documentation with the GLO establishing the first ever major offshore carbon sequestration site in the United States. The lease comprises more than 40,000 acres immediately adjacent to the Beaumont and Port Arthur, Texas industrial corridor and maintains an estimated sequestration capacity of 225 - 275 million metric tons of CO2. Talos will be the operator and holds a 50% equity interest. The company established a technical alliance with Core Lab to advance CCS site characterization, including stratigraphic evaluation wells, reservoir core sampling, geological assessment and rock and fluid sample analysis, all of which are critical inputs for EPA Class VI permit applications. The alliance also provides a framework for future collaboration around transparent CO2 stream monitoring and verification.

07:05 EDT Chicago Atlantic funds $30M senior secured credit facility for Florida operator - Chicago Atlantic Real Estate Finance announced it led a $30 million senior secured credit facility to a private, vertically integrated, single-state cannabis operator in Florida. At closing, Chicago Atlantic funded $17.5 million of its total $22.5 million commitment. The facility will fund a new cultivation and processing facility in Florida that is expected to be fully operational early this year, repay existing indebtedness and build out over 20 dispensaries during the next two years. Since completing its initial public offering in December 2021, Chicago Atlantic has funded a total of $73.6 million of principal under 7 new loans and credit facilities to 6 separate operators as well as an additional $36.1 million of principal to existing borrowers under current credit facilities in 18 states for total loan fundings of approximately $109.7 million.

07:04 EDT Maverix Metals sees FY22 attributable GEOs 32,000-35,000 - The company said, "Maverix continues to expect 32,000 to 35,000 attributable GEOs for 2022 at approximately a 90% cash margin with approximately 99% of expected revenue derived from gold and silver. On March 2, 2022, Polymetal International plc ("Polymetal") announced the current and devastating conflict in Ukraine and related economic and political developments are likely to require a lot of management efforts to maintain Polymetal's performance. However, despite a wide range of uncertainties Polymetal will be working under in 2022, it is Polymetal's current intention to operate as normally as possible but remain agile to evolving circumstances. Polymetal also reiterated its current production guidance for 2022. Maverix has a 2.5% gross revenue royalty on the Omolon hub operation owned by Polymetal and located in Magadan Region, Russia. On March 9, 2022, Polymetal stated that all its operations in Russia continue undisrupted."

07:03 EDT LGI Homes opens Phoenix area community in Buckeye - LGI Homes announced the opening of Terravista, its newest community in the Phoenix market. Located in Buckeye, Arizona, this incredible new community offers brand-new single-family homes filled with upgrades, minutes from major employers and popular amenities.

07:02 EDT Verizon announces nearly $1B in awards from U.S. Department of Defense - The U.S. Department of Defense has awarded Verizon Public Sector three Enterprise Infrastructure Solutions task order awards worth $966.5M. Verizon will provide network modernization services and technical support services to the Pentagon, the DOD National Capital Region and Fort Belvoir. Under the Pentagon task order valued at $515.3M, Verizon will partner with the DOD to transition the entire Pentagon military and civilian population from copper-based telephony to advanced internet protocol-based services, providing a converged-enterprise environment for the Pentagon's voice and data services. This includes converting more than 52,000 voice lines to an integrated IP environment with optimized voice and video services. Verizon professional services will provide the DOD with a dedicated support team to help plan, design and implement network upgrades and new equipment at the Pentagon. The second award with DOD-NCR is a $432.9M task order. Verizon will deliver core voice, transport, internet and professional services to over 370 locations within the DOD-NCR. DOD-NCR leads an interagency group responsible for the homeland security and defense of the Washington, D.C. area and surrounding counties in Virginia and Maryland. Finally, Verizon has been awarded an $18.3M task order to provide communications technology infrastructure including core voice, transport, internet and managed services at Fort Belvoir. The U.S. Army garrison provides logistical, intelligence and administrative support to a diverse mix of commands, activities and agencies in the Washington, D.C. area. Verizon will also work hand-in-hand with the DOD to help develop and implement a long-term, strategic IT vision and plan to promote innovation to remain on the leading edge as technology transforms and improves.

06:51 EDT Spire Global announces space-as-a-service agreement with NorthStar Earth & Space - Spire Global announced a new space-as-a-service agreement with NorthStar Earth & Space to build a constellation of satellites focused on space-situational awareness and debris monitoring. The first award within the contract is for three satellites, with pre-agreed options for NorthStar to scale the constellation to dozens of satellites as their business operational needs grow. With this dedicated constellation, NorthStar will be able to monitor space from space, delivering timely and precise orbit determination, collision avoidance, navigation services, and proximity warnings for cyber security to the global satellite community. The mission will encompass the development of Spire's first 12U satellites as the company continues to expand the power, volume, and edge-computing capacity available to applications deployed on Spire's space platform.

06:49 EDT Land's End CFO sees FY22 sales growth higher in 'back half of the year' - Jim Gooch, President and CFO, stated, "We are very pleased with the performance we delivered in 2021, despite the supply chain challenges in the back half of the year. For fiscal 2022, we expect year-over-year sales growth to be higher in the back half of the year, as we lap strong demand from the first half of 2021 and inventory constraints we experienced in the back half of 2021. While we navigate the macro headwinds through the remainder of fiscal 2022, we remain confident in our business model and ability to meet our long-term targets."

06:43 EDT Bridgetown 2 Holdings shareholders approve combination with PropertyGuru - Bridgetown 2 Holdings (BTNB) announced that Bridgetown 2 shareholders approved the previously announced business combination with PropertyGuru, which it calls "Southeast Asia's leading property technology company,", at an extraordinary meeting of shareholders. As previously disclosed, the transaction is expected to close March 17, subject to the satisfaction or waiver of customary closing conditions. Following the close of the business combination, PropertyGuru's ordinary shares are expected to begin trading on the New York Stock Exchange on March 18, under the ticker symbol "PGRU."

06:37 EDT ChromaDex issued additional U.S. continuation patent for Niagen - ChromaDex was granted an additional continuation patent adding to its global patent portfolio surrounding nicotinamide riboside and other nicotinamide adenine dinucleotide - NAD - precursors. This newly granted continuation patent reinforces a recently granted patent. ChromaDex currently owns and licenses a patent portfolio of over 40 granted patents relating to Niagen and other precursors of NAD. Niagen is the sole active ingredient in ChromaDex's flagship product, Tru Niagen. This new patent relates to a novel method of making nicotinamide riboside chloride salt.

06:34 EDT Shoe Carnival raises quarterly dividend 29% to 9c from 7c per share - The quarterly cash dividend will be paid on April 18 to shareholders of record as of the close of business on April 4. Additionally, the company has $50M available in calendar 2022 for future repurchases under its share repurchase program.

06:08 EDT Coda Octopus expects CFO to retire in FY22 - The company said, "We anticipate bolstering our management team in the fiscal year 2022 with a focus on complementing our management with business development and marketing resource. We also expect our current CFO, who has held this position for over 12 years to retire in this fiscal year and we will be bringing on board in the next 30 to 60 days, a new CFO. Alongside the financial responsibilities of the Group, we anticipate the new CFO will be actively leading our investor relations program and earnings call and future M&A strategy"

05:54 EDT NLRB issues complaint against Starbucks - The National Labor Relations Board on Tuesday issued a complaint against Starbucks over accusations that it retaliated against two employees seeking to unionize their store in Phoenix. The formal complaint contends that Starbucks issued a written warning to one employee and suspended her, and rejected the scheduling preferences of a second employee, leading to her termination, because the employees supported the union.

05:36 EDT Prothena announces new preclinical data from dual Ass/tau vaccine for AD - Prothena presented new preclinical data from both its dual Ass/tau vaccine for the potential treatment and prevention of Alzheimer's disease, or AD, and from its tandem C-terminal a-synuclein vaccine programs for the potential treatment and prevention of Parkinson's disease, or PD, and related synucleinopathies. The data were presented at the International Conference on Alzheimer's and Parkinson's Diseases, taking place March 15-20, 2022, in Barcelona, Spain. Preclinical data on Prothena's dual Ass/tau vaccine were presented in an oral presentation. Prothena's dual Ass/tau vaccines were described as linear peptide conjugates designed to prevent the two key processes associated with AD: the formation of Ass-plaque and the development of intraneuronal tau tangles. The incremental results from preclinical studies support the continued development of this dual-epitope vaccine for the treatment and prevention of AD. Specifically, the findings presented at AD/PD 2022 provide proof of concept in multiple preclinical species for Prothena's dual Ass/tau vaccine to address the desirable attributes of quantity, quality and safety that have prevented the advancement of safe and effective vaccines for the treatment or prevention of AD. From a quantity standpoint, results demonstrated both the generation of robust and balanced immunogenic responses against pathogenic Ass and tau in multiple animal species, demonstrating the ability to overcome immunodominance. For quality, sera from immunized animals inhibited the binding of soluble Ass aggregates to cultured hippocampal neurons and bound to Ass plaques and tau tangles in human AD brain sections at titers expected to be achieved in the central nervous system in vivo, potentially demonstrating strong immunoreactivity to Ass and tau pathology. The antibodies generated by these vaccines also induced phagocytosis and blocked binding of tau to heparin, an analog of heparan sulfat, or HS. Tau-HS interactions are believed to be involved in both the secretion of tau and its subsequent internalization into neurons. For safety, the sera from immunized non-human primates did not generate measurable cytotoxic T-cell responses to endogenous Ass or tau proteins. Prothena presented preclinical data from a study of Prothena's tandem C-terminal a-synuclein vaccine in a poster presentation titled: Development of C-Terminal a-Synuclein Vaccine for Treatment and Prevention of Parkinson's Disease and Other Synucleinopathies. The findings demonstrate that the lead vaccine candidate with tandem C-terminal a-synuclein peptides resulted in titers, with robust binding to pathogenic a-synuclein and inhibition of uptake of soluble a-synuclein aggregates into cells, when compared to immunization with vaccines containing a single peptide sequence. The robust and functional characteristics of the immune response following vaccination support the further development of this approach for the potential treatment and prevention of PD and related synucleinopathies.

05:30 EDT Bridgetown 2 Holdings shareholders approve combination with PropertyGuru - Bridgetown 2 Holdings announced that Bridgetown 2 shareholders approved the previously announced business combination with PropertyGuru, Southeast Asia's property technology company, at an extraordinary meeting of shareholders.

05:27 EDT Genentech announces new Evrysdi data from SUNFISH trial - Genentech, a member of Roche, announced new data for Evrysdi in spinal muscular atrophy, or SMA. Presentations included new three-year data from the SUNFISH study which further confirmed the long-term efficacy and safety of Evrysdi in a broad population of people aged 2-25 years with Type 2 or Type 3 SMA. Additional presentations included exploratory two-year efficacy data from SUNFISH Part 2, demonstrating improvement in, or stabilization of, motor function with Evrysdi compared to an untreated external control group. Genentech also announced updated interim data from the RAINBOWFISH study in pre-symptomatic babies with SMA under two months of age. The data were presented at the Muscular Dystrophy Association, or MDA, Clinical and Scientific Conference, March 13-16. In the SUNFISH study, the increase in Motor Function Measure 32, or MFM-32, total score from baseline previously observed at year one was maintained through year three in people treated with Evrysdi. The increases in Revised Upper Limb Module, or RULM, and Hammersmith Functional Motor Scale Expanded total scores from baseline were also sustained between year one and year three. Evrysdi was well-tolerated over the three-year time period in the SUNFISH study. The overall rate of adverse events, or AEs, in SUNFISH decreased over three years, and a trend towards a lower rate of serious adverse events, or SAEs, was observed in the third year of treatment. Overall, AEs and SAEs were reflective of the underlying disease and no treatment-related AEs led to withdrawal from the study. In addition, for the first time, an external comparator analysis has been done for SUNFISH two-year data with an untreated control group. The weighted exploratory analyses of MFM total scores showed that in SUNFISH Part 2, the proportion of patients demonstrating a marked improvement or stabilization were more likely in patients who were on Evrysdi for 24 months than those in the untreated comparator group. Updated interim data from the RAINBOWFISH study were also shared, demonstrating the safety and efficacy of Evrysdi for newborns. In January, the U.S. Food and Drug Administration granted priority review of a supplemental new drug application for the use of Evrysdi to treat pre-symptomatic babies under two months of age with SMA.

05:22 EDT Ipsen to invest in new electronic autoinjector - Ipsen announced it will invest in a new electronic autoinjector for Somatuline Autogel/Somatuline Depot, to deliver further innovation in the class with the aim of improving administration and the injection experience for patients. The new device will be made in collaboration with Phillips-Medisize and will be accompanied by enhanced investment in Ipsen's Signes manufacturing site in France. This step further builds on Ipsen's 20 years' experience with Somatuline Autogel / Somatuline Depot, with this announcement marking the fourth generation of devices for its administration.

05:17 EDT NortonLifeLock issues statement as CMA refers Avast merger for further review - NortonLifeLock (NLOK) released the following statement related to the status of the final remaining regulatory approval for NortonLifeLock's recommended merger with Avast (AVASF): "Based upon potential impact in the U.K. market, the CMA intends to refer the Merger to a Phase 2 investigation if the company does not offer Phase 1 remedies. The decision is surprising. We believe this transaction can only benefit consumers across the globe, including in the U.K., through increased innovation and greater consumer freedom and choice beyond big tech platform providers in the burgeoning Cyber Safety market. Regulators from across the globe, including the US Department of Justice, and in Europe the German Federal Cartel Office, and the Spanish National Markets and Competition Commission, have reviewed and cleared the transaction. NortonLifeLock remains confident that the transaction should be approved and does not intend to propose any Phase 1 remedies. The company will continue to constructively engage with the CMA and their review."

05:11 EDT Ambarella, Helm.ai announce ADAS software integration - Ambarella and Helm.ai, announced a new perception software release for the Ambarella CVflow AI SoC architecture that makes Helm.ai's advanced driver assistance system, or ADAS, software available to the ecosystem of customers and partners built around the Ambarella platform. This new integration allows both companies to rapidly iterate on technical approaches that meet the latest automotive market needs, while offering combined hardware and software solutions to joint customers.